Researchers are investigating retatrutide, a innovative dual-agonist targeting both GLP-1 and GIP receptors. This medication demonstrates remarkable potential in promoting weight loss results . Early clinical https://reta616011.blogdigy.com/the-new-hope-for-obesity-treatment-72072915